Skip to search boxSkip to navigationSkip to main content

Cytotoxic N-[4-(3-aryl-3-oxo-1-propenyl)phenylcarbonyl]-3,5-bis(phenylmethylene)-4- piperidones and related compounds

  • Jonathan R. Dimmock(corresponding author)
    ,
  • Amitabh Jha
    ,
  • Gordon A. Zello
    ,
  • J. Wilson Quail
    ,
  • Eliud O. Oloo
    ,
  • Kurt H. Nienaber
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

A series of 4-carboxychalcones 1 were prepared and coupled to 3,5-bis(phenylmethylene)-4-piperidone (2) giving rise to a novel series of N-[4-(3-aryl-3-oxo-1-propenyl)phenylcarbonyl]-3,5-bis(phenylmethylene)-4- piperidones (3). Molecular simplification of the amides 3 led to the formation of the corresponding N-(3-aryl-1-oxo-2-propenyl)-3,5-bis(phenylmethylene)-4-piperidones (4). A cytotoxic evaluation of the compounds in series 1-4 utilized murine P388 and L1210 cells as well as human Molt 4/C8 and CEM T-lymphocytes. In general, the compounds displayed significant toxicity; the IC50 values of 54% of the enones were less than 10 μM when all four screens were considered and less than 1 μM for all members of series 3 in the P388 assay. Various correlations were established between the potencies of the compounds in series 1, 3 and 4 and the Hammett σ, Hansch π and molecular refractivity constants of the aryl substituents. Several torsion angles and interatomic distances of five representative compounds in series 3 and 4 were determined by X-ray crystallography, some of which contributed to the observed bioactivity. The marked cytotoxicity and lack of murine toxicity of most of the compounds described in this study, as well as their selective toxicity towards different tumour cell lines, revealed that development of the enones 2-4 as novel candidate antineoplastic agents should be pursued.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 961-972 (12 pages)

Journal (Volume, Issue Number)

European Journal of Medicinal Chemistry (Volume 37, Issue 12)

Publication milestones

  • Published - 12/01/2002

Publication status

Published - 12/01/2002

ISSN

0223-5234

Publication IDs

  • Scopus: 0036948054
  • PubMed: 12660021

Publication metrics

Metrics

SciVal
citations
46
Scopus
citations
SciVal
FWCI
0.56
SciVal
Author count
13
SciVal
Paper percentile
84
Fractional count
1
Fractional count
0.08
Fractional count
12
Fractional count
0.92
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
13
Citation count
51

Funding Details

The authors thank the following sources for financial support for this project namely Purdue Neuroscience Company, USA (J.R.D.), Natural Sciences and Engineering Research Council of Canada (J.W.Q.), University of Saskatchewan (E.O.O.), National Cancer Institute of Canada (T.M.A.), Flemish Fonds voor Geneeskundig Weterschappelijk Onderzoek (E.D.C., J.B.) and the National Institute of Neurological Disorders and Stroke (J.P.S.). The US National Cancer Institute is thanked for determining the bioevaluations using a panel of human tumour cell lines.
FundersFunding numbers
Flemish Fonds Voor Geneeskundig Weterschappelijk Onderzoek
-
National Cancer Institute of Canada
-
Purdue Neuroscience Company
-
NINDS
-
University of Saskatchewan
-
NSERC
-